Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury

Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury. Am J Physiol Renal Physiol 314: F736–F746, 2018. First published September 27, 2017; doi:10.1152/ajprenal.00414.2016.—The Notch pathway has been reported to control tissue damage in acute kidney diseases. To investigate potential beneficial nephroprotective effects of targeting Notch, we developed chemically functionalized -secretase inhibitors (GSIs) targeting -glutamyltranspeptidase (gamma-GT) and/or -glutamylcyclotransferase (gamma-GCT), two enzymes overexpressed in the injured kidney, and evaluated them in in vivo murine models of acute tubular and glomerular damage. Exposure of the animals to disease-inducing drugs together with the functionalized GSIs improved proteinuria and, to some extent, kidney dysfunction. The expression of genes involved in the Notch pathway, acute inflammatory stress responses, and the renin-angiotensin system was enhanced in injured kidneys, which could be downregulated upon administration of functionalized GSIs. Immunohistochemistry staining and Western blots demonstrated enhanced activation of Notch1 as detected by its cleaved active intra- cellular domain during acute kidney injury, and this was downregulated by concomitant treatment with the functionalized GSIs. Thus targeted gamma-secretase-based prodrugs developed as substrates for gamma-GT/ -GCT have the potential to selectively control Notch activation in kidney diseases with subsequent regulation of the inflammatory stress response and the renin-angiotensin pathways.